Its prediction application Alzheimer’s via mobile devices, phones and tablets, while it is an evolution of the ALTOIDA platform. This invaluable gift is to be given to all Greeks by scientists – researchers of the USA and the Ionian University.
Using this pioneering Alzheimer’s prediction application will be very easy via mobile devices, phones and tablets. It is a globally innovative technology of smart digital biomarkers, which recently won the highest distinction with the designation “cutting edge technology” by the American Drug Administration (FDA).
The action is part of the program of implementation and monitoring of a strategic translation research plan for the management of Alzheimer’s disease and related disorders in Greece and is coordinated by members of the Hellenic Initiative Against Alzheimer’s Disease.
The application aims at the modernization of personalized medicine in Greece through the creation of a mental health platform, with particular emphasis on the protection of mental health in people at high risk for dementia. Through the cooperation, diagnostic technologies of artificial intelligence and “active” digital biomarkers, which have already been tested and approved by the FDA on the other side of the Atlantic, will be adapted to the Greek parameters and will be developed.
Alzheimer’s – Application of artificial intelligence
A second important announcement is that the platform will be updated with the use of artificial intelligence by Greek scientists to predict Parkinson’s disease. State-of-the-art technology will be presented in Greece, on the occasion of the official launch of Digital Innovation HUB: Health Hub at the Thessaloniki International Fair (TIF).
Through the cooperation with the scientific network of Health Hub, which already consists of 25 partners, will be adapted to the Greek parameters and will develop diagnostic technologies of artificial intelligence and “active” digital biomarkers, which have already been awarded in Europe and the United States. Of America.
“The new Parkinson’s platform could allow the prognostic diagnosis of neurodegenerative disorders in the general population, which in turn will allow preventive and therapeutic intervention in the early stages to delay onset and improve clinical outcomes. The platform has been configured using data from the last 20 years “, said during his stay in Corfu, Dr. Ioannis Tarnanas, scientific manager of Altoida.
Alzheimer’s – Parkinson’s
“The research team of the Laboratory of Bioinformatics and Human Electrophysiology has developed innovative computational techniques of Bioinformatics and Machine Learning in digital clinical data, in order to identify biomarkers that play an important role in the development of models and corresponding applications that will dopaminergic neurons in the vulnerable population “, said the scientific director of the Laboratory of Bioinformatics and Human Electrophysiology and president of the Research Center of the Ionian University Panagiotis Vlamos.
“Early test results in the BiHELB Brain Registry Prodromal PD At Risk Cohort (DNS2_PD) database found that the new platform has a pre-clinical Parkinson’s accuracy of 93%, while also offering approximately 91% sensitivity and 82% accuracy in predicting . This makes it about 2.6 times more sensitive than traditional neurological assessment tests and in addition it is much easier to use due to its ten-minute duration, “said Dr. I. Tarnanas.
source: ΑΠΕ – ΜΠΕ
READ ALSO